Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YJYouchao JiaXSXiuli SunHWHuihan Wang

Discussion

Loading...

Member takes

Overview

Multicenter study shows improved outcomes in Chinese patients with relapsed Hodgkin lymphoma, suggesting BV may be effective treatment option.

Key Points

  • This research aims to assess the clinical characteristics and treatment outcomes of brentuximab vedotin in Chinese patients with relapsed Hodgkin lymphoma.
  • Retrospective multi-center study across 11 medical centers in China
  • Evaluated patients with relapsed Hodgkin lymphoma receiving BV-based regimens
  • Collected data on therapeutic efficacy, toxicity, and survival outcomes
  • Enrolled 93 patients diagnosed with classical Hodgkin lymphoma
  • Achieved overall response rate of 90.63% with BV-based therapies
  • Reported progression-free survival rates of 75% at 1 year and 57.5% at 2 years

Cite This Study

Jia et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d72chttps://doi.org/10.1182/blood-2025-7142
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study2025
  2. 2Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis2025
  3. 3Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China2025
  4. 4Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data2024
  5. 5Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China2024 · 4 citations